{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:59:31Z","timestamp":1770814771880,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Graft engineering by CD34+ selection of peripheral blood progenitor cells (PBPC) has been used in non-Hodgkin lymphoma (NHL) with the aim to reduce relapse related to tumor cells within the graft. From September 1995 to January 2000, 39 patients with newly diagnosed (n = 31) or relapsed (n = 8) NHL were treated in our institution with myeloablative therapy followed by CD34+ selected autologous PBPC transplantation. Thirty-one patients were diagnosed with follicular lymphoma, and eight patients with mantle-cell lymphoma. All patients had advanced disease (26% of patients stage III and 74% stage IV, Ann Arbor classification). Induction therapy resulted in a complete remission in 17 patients and a partial remission in 22 patients. PBPC were mobilized after cytotoxic chemotherapy with granulocyte colony-stimulating factor support. CD34+ selection was performed using immunomagnetic beads (Baxter Isolex 300SA or 300i Magnetic Cell Separation System). Most patients (85%) received total body irradiation and high-dose cyclophosphamide as myeloablative regimen. Twelve patients also received rituximab 375 mg\/m2 before radiation and before the start of the cyclophosphamide treatment. The mean CD34+ cell number for transplantation was 6.5 \u00d7 106 CD34+ cells\/kg of body weight. Platelet recovery (&amp;gt;20,000\/\u03bcl median on day 13) and leukocyte recovery (&amp;gt;1,000\/\u03bcl median on day 12) were within expected range. The estimated median follow-up was 47 months. The probabilities of freedom from progression, overall survival, and event-free survival 4 years after transplantation were 96%, 90%, and 87%, respectively, for patients with follicular lymphoma and 42%, 63%, and 33%, respectively, for patients with mantle-cell lymphoma. Risk factors for relapse were age and extranodal manifestation of disease. The rate of lethal infections in the 12-month follow-up period was 8%. We conclude that CD34+ selection of autologous transplants following myeloablative therapy is feasible and results in long-term remission in the majority of patients, but the procedure is probably related to a higher rate of lethal infections.<\/jats:p>","DOI":"10.1634\/stemcells.2005-0613","type":"journal-article","created":{"date-parts":[[2007,1,9]],"date-time":"2007-01-09T17:17:50Z","timestamp":1168363070000},"page":"228-235","source":"Crossref","is-referenced-by-count":19,"title":["Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34+-Selected Peripheral Blood Progenitor Cells"],"prefix":"10.1093","volume":"25","author":[{"given":"Mathias","family":"Witzens-Harig","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conny","family":"Heilmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kornacker","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[{"name":"Central Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fruehauf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,1,1]]},"reference":[{"key":"2022011304423982900_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood.V67.2.529.529","article-title":"Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma","volume":"67","author":"Korbling","year":"1986","journal-title":"Blood"},{"key":"2022011304423982900_bib2","first-page":"94","article-title":"Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor","volume":"18","author":"Haas","year":"1990","journal-title":"Exp Hematol"},{"issue":"7 (suppl 1)","key":"2022011304423982900_bib3","first-page":"13","article-title":"Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation","author":"Ho","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2022011304423982900_bib4","first-page":"691","article-title":"Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g\/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma","volume":"17","author":"Goldschmidt","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2022011304423982900_bib5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1200\/JCO.1996.14.4.1306","article-title":"Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma","volume":"14","author":"Marit","year":"1996","journal-title":"J Clin Oncol"},{"key":"2022011304423982900_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.1997.3933207.x","article-title":"Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone","volume":"99","author":"Schlenk","year":"1997","journal-title":"Br J Haematol"},{"key":"2022011304423982900_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.1999.01405.x","article-title":"Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: An update on 100 patients","volume":"105","author":"Fruehauf","year":"1999","journal-title":"Br J Haematol"},{"key":"2022011304423982900_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/annonc\/mdi264","article-title":"Chemotherapy dose intensity in non-Hodgkin's lymphoma: Is dose intensity an emerging paradigm for better outcomes?","volume":"16","author":"Gregory","year":"2005","journal-title":"Ann Oncol"},{"key":"2022011304423982900_bib9","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"2022011304423982900_bib10","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"2022011304423982900_bib11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"2022011304423982900_bib12","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87\u20132 protocol\u2014A Groupe d'Etude des Lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022011304423982900_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(93)92560-G","article-title":"Gene-marking to trace origin of relapse after autologous bone-marrow transplantation","volume":"341","author":"Brenner","year":"1993","journal-title":"Lancet"},{"key":"2022011304423982900_bib14","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1182\/blood.V79.4.1074.bloodjournal7941074","article-title":"Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique","volume":"79","author":"Sharp","year":"1992","journal-title":"Blood"},{"key":"2022011304423982900_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/scd.1.1993.2.247","article-title":"Immunomagnetic positive selection and colony culture of CD34+ cells from blood","volume":"2","author":"Law","year":"1993","journal-title":"J Hematother"},{"key":"2022011304423982900_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/stem.5530120116","article-title":"CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors","volume":"12","author":"Fruehauf","year":"1994","journal-title":"Stem Cells"},{"key":"2022011304423982900_bib17","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1182\/blood.V89.10.3763","article-title":"Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma","volume":"89","author":"Voso","year":"1997","journal-title":"Blood"},{"key":"2022011304423982900_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2141.1999.01171.x","article-title":"Autografting with CD34+ peripheral blood stem cells: Retained engraftment capability and reduced tumour cell content","volume":"104","author":"Voso","year":"1999","journal-title":"Br J Haematol"},{"key":"2022011304423982900_bib19","first-page":"1858","article-title":"Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma","volume":"93","author":"Vescio","year":"1999","journal-title":"Blood"},{"key":"2022011304423982900_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cyto.990110203","article-title":"High gradient magnetic cell separation with MACS","volume":"11","author":"Miltenyi","year":"1990","journal-title":"Cytometry"},{"key":"2022011304423982900_bib21","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/1097-0142(19891001)64:7<1388::AID-CNCR2820640703>3.0.CO;2-0","article-title":"Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma","volume":"64","author":"Ho","year":"1989","journal-title":"Cancer"},{"key":"2022011304423982900_bib22","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood.V84.10.3550.3550","article-title":"Soluble CD4, soluble CD8, soluble CD25, lymphopoieitic recovery and endogenous cytokines after high-dose therapy and blood stem cell transplantation","volume":"84","author":"Ho","year":"1994","journal-title":"Blood"},{"key":"2022011304423982900_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma In first or partial remission: Results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"2022011304423982900_bib24","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood.V83.12.3787.3787","article-title":"Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma","volume":"83","author":"Haas","year":"1994","journal-title":"Blood"},{"key":"2022011304423982900_bib25","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.1995.13.10.2547","article-title":"Factors that influence collection and engraftment of autologous peripheral blood stem cells","volume":"13","author":"Bensinger","year":"1995","journal-title":"J Clin Oncol"},{"key":"2022011304423982900_bib26","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/JCO.2000.18.6.1360","article-title":"Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy","volume":"18","author":"Siena","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022011304423982900_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2004.04951.x","article-title":"Infused CD34+ cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patient with diffuse large-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy","volume":"125","author":"Blystad","year":"2004","journal-title":"Br J Haematol"},{"key":"2022011304423982900_bib28","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"2022011304423982900_bib29","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.1996.14.5.1447","article-title":"High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma","volume":"14","author":"Bensinger","year":"1996","journal-title":"J Clin Oncol"},{"key":"2022011304423982900_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood.V86.1.390.bloodjournal861390","article-title":"Transplantation of peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma","volume":"86","author":"Schiller","year":"1995","journal-title":"Blood"},{"key":"2022011304423982900_bib31","first-page":"51","article-title":"Simultaneous immunomagnetic CD34+ cell selection in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphomas","volume":"7","author":"Mohr","year":"2001","journal-title":"Clinical Cancer Res"},{"key":"2022011304423982900_bib32","first-page":"481","article-title":"In-vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with rituximab and high-dose therapy","volume":"92","author":"Gianni","year":"1998","journal-title":"Blood"},{"key":"2022011304423982900_bib33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/annonc\/mdh090","article-title":"Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study","volume":"15","author":"Belhadj","year":"2004","journal-title":"Ann Oncol"},{"key":"2022011304423982900_bib34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"2022011304423982900_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2141.2000.02084.x","article-title":"In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma","volume":"109","author":"Voso","year":"2000","journal-title":"Br J Haematol"},{"key":"2022011304423982900_bib36","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","article-title":"All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment","volume":"78","author":"Gribben","year":"1991","journal-title":"Blood"},{"key":"2022011304423982900_bib37","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.1997.15.6.2288","article-title":"Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study","volume":"15","author":"McQuaker","year":"1997","journal-title":"J Clin Oncol"},{"key":"2022011304423982900_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V91.1.331","article-title":"Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: Less than one log difference between bone marrow and peripheral blood sources","volume":"91","author":"Leonard","year":"1998","journal-title":"Blood"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Fstemcells.2005-0613","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/stemcells.2005-0613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/stemcells.2005-0613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/25\/1\/228\/41961859\/stmcls_25_1_228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/25\/1\/228\/41961859\/stmcls_25_1_228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:51:25Z","timestamp":1642560685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/25\/1\/228-235\/6401700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,1]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/stemcells.2005-0613","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,1,1]]},"published":{"date-parts":[[2007,1,1]]}}}